She spent decades of her life practicing medicine, so when Miami pediatrician Elsie Davila was diagnosed with ovarian cancer in 2009, she knew every reason to be afraid.

Ovarian cancer is the No. 1 killer among gynecological cancers. Survival, if not discovered early, can be a mere 20 to 30 percent. Making matters worse, the disease is difficult to detect until it spreads to other organs.

“I knew it was bad. I definitely had my concerns,” said Davila, 53, of Doral.

According to American Cancer Society estimates for 2012, about 15,500 American women will likely die from ovarian cancer this year. About 22,280 more women will be diagnosed.

“Compared to other cancers (with prostate at No. 1 followed by breast, lung and colon) the numbers are small but the disease is most deadly,” said Davila’s doctor, Dr. Samar Schuman, an assistant professor of gynecologic oncology at the University of Miami’s Miller School of Medicine.

While statistics are staggering, new hope is on the horizon.

After two years of surgeries and several chemotherapy programs proved ineffective, in April 2012, Davila became one of the first 20 women at the University of Miami Hospital to receive the latest, most promising treatment available for ovarian cancer — hypothermic intraperitoneal chemotherapy.

The hospital is the only medical facility south of Moffit Cancer Center in Tampa to offer the treatment, called HIPEC.

The New England Journal of Medicine in 2006 reported a national study that showed HIPEC can slow the cancer’s progression and increase patient survival rate.

More recent studies from France, Italy, Australia and Spain tout similar results.

University of Miami Hospital began using the procedure in November 2010. Schuman said all patients are faring well but only time will tell how effective HIPEC is for each individual.

“It’s too soon to have hard data yet, but the procedure is proven to be safe and [results] have been encouraging. Theoretically, I am convinced it is a step in the right direction,” Schuman said.

Simply described, HIPEC is a 90-minute wash of the entire peritoneal (abdominal) cavity using an intense solution of chemotherapy heated to about 107 degrees Fahrenheit.

Typically, Schuman said, the accepted standard treatment for the disease is the surgical removal of tumors followed by rounds of intravenous chemotherapy. Additional rounds of chemo, delivered by tubes placed in the abdomen directly at the disease, provide more punch.

Still, ovarian cancer returns in about 75 percent of patients.

Dr. Michel Vulfovich, a chemotology oncology physician at Memorial Cancer Institute at Memorial Regional Hospital in Hollywood, said ovarian cancer can recur a month after treatment.

“It only takes one cell resistant to the therapy for the cancer to start again. The likelihood of cancer in other parts of the body is more than possible — it is probable,” Vulfovich said.

Another problem is that different kinds of ovarian cancers act uniquely from one woman to the next.

“We’ve treated some with very advanced ovarian cancer who were cured and others who came in early who were not. We can have 10 patients with the disease and 10 totally, completely different cases,” Vulfovich said. “We just don’t fully understand the biology of the tumors.”